Hu Dong, Ren Jianan, Wang Gefei, Li Guanwei, Liu Song, Yan Dongsheng, Gu Guosheng, Zhou Bo, Wu Xiuwen, Chen Jun, Ding Chao, Wu Yin, Wu Qin, Liu Naicheng, Li Jieshou
Department of Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
J Clin Gastroenterol. 2014 Oct;48(9):790-5. doi: 10.1097/MCG.0000000000000041.
To examine the efficiency of exclusive enteral nutrition (EEN) in relieving inflammatory bowel stricture in patients with Crohn's disease (CD).
Patients with CD usually develop bowel strictures due to transmural edema of intestinal wall, which can potentially be managed with conservative medical treatment. Previous studies showed that EEN therapy could induce clinical remission through its anti-inflammation effect.
We achieved a prospective observational study. CD patients with inflammatory bowel stricture were preliminarily differentiated from a fibrous one, and further treated with EEN therapy for 12 weeks. Demographics and clinical variables were recorded. Nutritional (body mass index, albumin, pre-albumin, transferrin, etc.), inflammatory (C-reactive protein, erythrocyte sedimentation rate, white blood cell, etc.), and radiologic parameters (bowel wall thickness, luminal diameter, and luminal cross-sectional area) were evaluated at baseline, week 4, and week 12, respectively.
Between May 2012 and January 2013, 65 patients with CD were preliminarily diagnosed with inflammatory bowel stricture and 6 patients were further excluded. Among the remaining 59 cases, 50 patients (84.7%) finished the whole EEN treatment, whereas the other 9 patients (15.3%) gained progressive bowel obstruction resulting in surgery. Intention-to-treat analyses showed that 48 patients (81.4%) achieved symptomatic remission, 35 patients (53.8%) achieved radiologic remission, and 42 patients (64.6%) achieved clinical remission. Among those patients who complete the whole EEN therapy, inflammatory, nutritional, and radiologic parameters improved significantly compared with baseline. Of note, the average luminal cross-sectional area at the site of stricture increased approximately 331% at week 12 (195.7 ± 18.79 vs. 59.09 ± 10.64 mm, P<0.001).
EEN therapy can effectively relieve inflammatory bowel stricture in CD, which replenishes roles of enteral nutrition in the treatment of CD. Further studies are expected to investigate the underlying mechanisms of this effect in the future.
探讨全肠内营养(EEN)缓解克罗恩病(CD)患者炎症性肠狭窄的疗效。
CD患者通常因肠壁透壁性水肿而发生肠狭窄,这有可能通过保守药物治疗来处理。既往研究表明,EEN疗法可通过其抗炎作用诱导临床缓解。
我们进行了一项前瞻性观察性研究。将患有炎症性肠狭窄的CD患者与纤维性狭窄患者初步区分开来,并进一步接受EEN治疗12周。记录人口统计学和临床变量。分别在基线、第4周和第12周评估营养指标(体重指数、白蛋白、前白蛋白、转铁蛋白等)、炎症指标(C反应蛋白、红细胞沉降率、白细胞等)和放射学参数(肠壁厚度、管腔直径和管腔横截面积)。
在2012年5月至2013年1月期间,65例CD患者初步诊断为炎症性肠狭窄,6例患者被进一步排除。在其余59例患者中,50例患者(84.7%)完成了整个EEN治疗,而其他9例患者(15.3%)出现进行性肠梗阻而接受手术。意向性分析显示,48例患者(81.4%)实现了症状缓解,35例患者(53.8%)实现了放射学缓解,42例患者(64.6%)实现了临床缓解。在完成整个EEN治疗的患者中,与基线相比,炎症、营养和放射学参数有显著改善。值得注意的是,在第12周时,狭窄部位的平均管腔横截面积增加了约331%(195.7±18.79 vs. 59.09±10.64 mm,P<0.001)。
EEN疗法可有效缓解CD患者的炎症性肠狭窄,这补充了肠内营养在CD治疗中的作用。预计未来将进一步研究这种作用的潜在机制。